- $200.88m
- $201.01m
- €51.90m
- 44
- 28
- 46
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.64 | ||
| Price to Tang. Book | 3.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.76% | ||
| Return on Equity | -14.28% | ||
| Operating Margin | -24.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 68.97 | 56.16 | 12.11 | 49.58 | 51.9 | 35.31 | 73.69 | -8.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Directors
- Herve Brailly CSU (59)
- Mondher Mahjoubi CMG (62)
- Irina Staatz-Granzer VSU (61)
- Laure-Helene Mercier CFO (42)
- Yannis Morel EVP (47)
- Jennifer Butler EVP (44)
- Joyson Karakunnel EVP (50)
- Eric Vivier SVP (56)
- Odile Laurent VPR (59)
- Odile Belzunce VPR (40)
- Frederique Brune VPR (55)
- Tracy Rossin VPR (43)
- Pascale Boissel IND (54)
- Gilles Brisson IND (69)
- Veronique Chabernaud IND (59)
- Patrick Langlois IND (75)
- Jean-Yves Blay SUB (58)
- Mailys Ferrere SUB (58)
- Marcus Schindler SUB (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 23rd, 1999
- Public Since
- October 31st, 2006
- No. of Employees
- 179
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 80,841,988
- Address
- 117 avenue de Luminy, Bp 30191, MARSEILLE, 13009
- Web
- https://www.innate-pharma.com/
- Phone
- +33 430303030
- Contact
- Henry Wheeler
- Auditors
- Deloitte & Associes
Similar to IPHA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:11 UTC, shares in Innate Pharma SA are trading at $2.48. This share price information is delayed by 15 minutes.
Shares in Innate Pharma SA last closed at $2.48 and the price had moved by -24.04% over the past 365 days. In terms of relative price strength the Innate Pharma SA share price has underperformed the S&P500 Index by -38.66% over the past year.
The overall consensus recommendation for Innate Pharma SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Innate Pharma SA does not currently pay a dividend.
Innate Pharma SA does not currently pay a dividend.
Innate Pharma SA does not currently pay a dividend.
To buy shares in Innate Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.48, shares in Innate Pharma SA had a market capitalisation of $200.88m.
Here are the trading details for Innate Pharma SA:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IPHA
Based on an overall assessment of its quality, value and momentum Innate Pharma SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Innate Pharma SA is $7.33. That is 195.66% above the last closing price of $2.48.
Analysts covering Innate Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.38 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innate Pharma SA. Over the past six months, its share price has underperformed the S&P500 Index by -8.55%.
As of the last closing price of $2.48, shares in Innate Pharma SA were trading -7.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Innate Pharma SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Innate Pharma SA's management team is headed by:
- Herve Brailly - CSU
- Mondher Mahjoubi - CMG
- Irina Staatz-Granzer - VSU
- Laure-Helene Mercier - CFO
- Yannis Morel - EVP
- Jennifer Butler - EVP
- Joyson Karakunnel - EVP
- Eric Vivier - SVP
- Odile Laurent - VPR
- Odile Belzunce - VPR
- Frederique Brune - VPR
- Tracy Rossin - VPR
- Pascale Boissel - IND
- Gilles Brisson - IND
- Veronique Chabernaud - IND
- Patrick Langlois - IND
- Jean-Yves Blay - SUB
- Mailys Ferrere - SUB
- Marcus Schindler - SUB